Zobrazeno 1 - 10 of 359 pro vyhledávání: '"Np, Restifo"'
3
Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice
Autor: Andrew Feldman, Np, Restifo, Hr, Alexander, Dl, Bartlett, Hwu P, Seth P, Sk, Libutti
Publikováno v: Europe PubMed Central
Gene therapy represents a possible alternative to the chronic delivery of recombinant antiangiogenic proteins to cancer patients. Inducing normal host tissues to produce high circulating levels of these proteins may be more effective than targeting a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::fde4687ad8b3512fe6eaab9968069a13
http://europepmc.org/abstract/med/10749112
Zobrazit plný text záznamu
5
Akademický článek
T cells lead the charge against solid tumors.
Autor: Kishton RJ; Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, USA. kishtonr@gmail.com., Restifo NP; Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, USA. nick@marbletx.com.; Medici Therapeutics, Boston, MA, USA. nick@marbletx.com.
Publikováno v: Nature cancer [Nat Cancer] 2024 Dec 17. Date of Electronic Publication: 2024 Dec 17.
Zobrazit plný text záznamu
6
Akademický článek
LIM-domain-only 4 (LMO4) enhances CD8 + T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling.
Autor: Schelker RC; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany. roland.schelker@ukr.de.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. roland.schelker@ukr.de.; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. roland.schelker@ukr.de.; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany. roland.schelker@ukr.de., Fioravanti J; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mastrogiovanni F; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Baldwin JG; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Rana N; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Li P; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Chen P; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Vadász T; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Spolski R; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Heuser-Loy C; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Slavkovic-Lukic D; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Noronha P; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Damiano G; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Raccosta L; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy., Maggioni D; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy., Pullugula S; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Lin JX; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Oh J; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Grandinetti P; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lecce M; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Hesse L; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; University of Regensburg, Regensburg, Germany., Kocks E; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; University of Regensburg, Regensburg, Germany., Martín-Santos A; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Gebhard C; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Telford WG; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ji Y; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Restifo NP; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Russo V; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Rehli M; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Herr W; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.; National Center for Tumor Diseases, WERA Site, Würzburg-Erlangen-Regensburg-Augsburg, Germany.; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg, Regensburg, Germany., Leonard WJ; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. leonardw@nhlbi.nih.gov., Gattinoni L; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany. luca.gattinoni@lit.eu.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. luca.gattinoni@lit.eu.; University of Regensburg, Regensburg, Germany. luca.gattinoni@lit.eu.; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg, Regensburg, Germany. luca.gattinoni@lit.eu.
Publikováno v: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Aug 09; Vol. 9 (1), pp. 199. Date of Electronic Publication: 2024 Aug 09.
Zobrazit plný text záznamu
7
Akademický článek
Synthetic soldiers: Turning T cells into immortal warriors.
Autor: Restifo NP; Marble Therapeutics , Boston, MA, USA.; Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health , Bethesda, MD, USA., Gattinoni L; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; University of Regensburg , Regensburg, Germany.; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg , Regensburg, Germany.
Publikováno v: The Journal of experimental medicine [J Exp Med] 2024 May 06; Vol. 221 (5). Date of Electronic Publication: 2024 Apr 18.
Zobrazit plný text záznamu
8
Akademický článek
Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells.
Autor: Islam SMR; Surgery Branch, NCI, NIH, Bethesda, Maryland.; Center for Cell-Based Therapy, NCI, NIH, Bethesda, Maryland., Maeda T; Surgery Branch, NCI, NIH, Bethesda, Maryland.; Center for Cell-Based Therapy, NCI, NIH, Bethesda, Maryland., Tamaoki N; Surgery Branch, NCI, NIH, Bethesda, Maryland.; Center for Cell-Based Therapy, NCI, NIH, Bethesda, Maryland., Good ML; Surgery Branch, NCI, NIH, Bethesda, Maryland.; Center for Cell-Based Therapy, NCI, NIH, Bethesda, Maryland., Kishton RJ; Surgery Branch, NCI, NIH, Bethesda, Maryland.; Center for Cell-Based Therapy, NCI, NIH, Bethesda, Maryland., Paria BC; Surgery Branch, NCI, NIH, Bethesda, Maryland., Yu Z; Surgery Branch, NCI, NIH, Bethesda, Maryland., Bosch-Marce M; Surgery Branch, NCI, NIH, Bethesda, Maryland., Bedanova NM; Experimental Pathology Laboratory, NCI, NIH, Bethesda, Maryland., Liu C; Transgenic Core, Division of Intramural Research, National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland., Kruhlak MJ; CCR Microscopy Core Facility, NCI, NIH, Bethesda, Maryland., Restifo NP; Surgery Branch, NCI, NIH, Bethesda, Maryland.; Center for Cell-Based Therapy, NCI, NIH, Bethesda, Maryland., Vizcardo R; Surgery Branch, NCI, NIH, Bethesda, Maryland.; Center for Cell-Based Therapy, NCI, NIH, Bethesda, Maryland.
Publikováno v: Cancer research communications [Cancer Res Commun] 2023 May 25; Vol. 3 (5), pp. 917-932. Date of Electronic Publication: 2023 May 25 (Print Publication: 2023).
Zobrazit plný text záznamu
9
Akademický článek
Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from induced pluripotent stem cells.
Autor: Tamaoki N; Surgery Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.; Center of Cell-based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Siebert S; Department of Molecular and Cellular Biology, University of California, Davis, Davis, CA 95616, USA., Maeda T; Surgery Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.; Center of Cell-based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Ha NH; Laboratory of Cancer Biology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Good ML; Surgery Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.; Center of Cell-based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Huang Y; Surgery Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.; Center of Cell-based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Vodnala SK; Surgery Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.; Center of Cell-based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Haro-Mora JJ; Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute/National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA., Uchida N; Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute/National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA., Tisdale JF; Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute/National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA., Sweeney CL; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Choi U; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Brault J; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Koontz S; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Malech HL; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Yamazaki Y; Immune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Isonaka R; Autonomic Medicine Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA., Goldstein DS; Autonomic Medicine Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA., Kimura M; Division of Gastroenterology, Hepatology & Nutrition, Developmental Biology, Center for Stem Cell and Organoid Medicine (CuSTOM), Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA., Takebe T; Division of Gastroenterology, Hepatology & Nutrition, Developmental Biology, Center for Stem Cell and Organoid Medicine (CuSTOM), Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA.; Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), and Division of Stem Cell and Organoid Medicine, Osaka University, Suita, Osaka 565-0871, Japan., Zou J; iPSC Core, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20892, USA., Stroncek DF; Cell Processing Section, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, MD 20892, USA., Robey PG; Skeletal Biology Section, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD 20892, USA., Kruhlak MJ; Laboratory of Cancer Biology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Restifo NP; Surgery Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.; Center of Cell-based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Vizcardo R; Surgery Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.; Center of Cell-based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Publikováno v: Cell reports methods [Cell Rep Methods] 2023 Apr 24; Vol. 3 (4), pp. 100460. Date of Electronic Publication: 2023 Apr 24 (Print Publication: 2023).
Zobrazit plný text záznamu
10
Akademický článek
Fine-tuning T cell function through engineered orthogonal chimeric cytokine receptors.
Autor: Kishton RJ; Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. kishtonr@gmail.com., Restifo NP; Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. drnickrestifo@gmail.com.
Publikováno v: Cell research [Cell Res] 2022 Nov; Vol. 32 (11), pp. 967-968.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje